At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Efavirenz and Ritonavir-boosted Darunavir on the Pharmacokinetics of the HMG CoA Reductase Inhibitor Pitavastatin
In Brief
A Phase 1 clinical trial evaluating Pitavastatin, Darunavir, and 2 other interventions for Hyperlipidemia and HIV. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The main goal of this study is to determine how taking efavirenz affects the levels of pitavastatin in the bloodstream when both drugs are taken together and to see how darunavir with ritonavir affects the levels of pitavastatin in the bloodstream. Secondary goals are to see how taking pitavastatin affects the levels in the blood of efavirenz when both drugs are taken together and to see how taking pitavastatin affects the levels in the blood of darunavir.
Study Details
Timeline
Interventions
Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.
Darunavir 400 mg tablets x 2 taken daily in Arm B
Ritonavir 100 mg tablets taken daily in Arm B
Efavirenz 600 mg tablets taken at bedtime in Arm A